Key result
Bosentan and sildenafil remain standard pediatric PAH treatments while riociguat and selexipag undergo evaluation.
Why the study?
PAH causes significant morbidity in childhood with limited approved therapies, necessitating a review of current treatments and emerging therapies being evaluated to limit off-label use.
This review highlights the current landscape of pediatric PAH treatment, emphasizing the need for more controlled trials and pharmacokinetic studies to optimize therapy in children.
Answers are grounded in this paper and cite their sources.
Supports bosentan and sildenafil as current pediatric PAH options; leaves open integration of riociguat and selexipag pending controlled trials.
Pulmonary arterial hypertension (PAH) is a devastating illness causing already significant morbidity in childhood. Currently approved treatment options for children comprise the endothelin receptor antagonist bosentan, as well as the phosphodiesterase-5 inhibitor sildenafil. But PAH treatment has advanced significantly over the past decade, and new classes of targeted drug therapies, such as stimulators of the soluble guanylate cyclase (riociguat) or prostacyclin receptor agonists (selexipag), are currently evaluated regarding their efficacy and safety in children, in order to limit off-label use. Due to the different etiologies in children, such as PAH-CHD, there is no evidence that initial combination therapy in children is superior to a mono-therapy with respect to survival. Special attention should also be paid to the pharmacology of PAH drugs in children, which might be impacted by ontogeny or drug-drug-interactions. Therapeutic drug monitoring may be useful in pediatric patients. There is a clear need for more controlled studies of PAH medications, alone or in combination therapy in the pediatric age group. Data from clinical trials as well as from patient registries should be pooled to optimize drug development and evaluation, trial design, and evidence-based pharmacotherapy in pediatric patients with PAH. In this review, the current treatment options of pediatric PAH are summarized, and an overview of new treatment concepts, which are already evaluated in adults, is presented.
No takes yet. Share an insight, caveat, or question.
Gorenflo et al. (2021) conducted a review in Pulmonary arterial hypertension (PAH). PAH medications (bosentan, sildenafil, riociguat, selexipag) was evaluated. Current treatment options for pediatric pulmonary arterial hypertension include bosentan and sildenafil, with newer targeted therapies like riociguat and selexipag currently under evaluation.
Synapse has enriched 10 related papers. Consider them for comparative context: